Navigation Links
Spectral announces 2007 financial results
Date:3/7/2008

TORONTO, March 7 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI) today announced its operational highlights and financial results for the fiscal year ended December 31, 2007.

"Spectral's priority is the commercialization of its EAA(TM) Endotoxin Activity Assay, the only FDA cleared assay for the measurement of endotoxin. Endotoxemia is a systemic response to bacterial toxins that can rapidly lead to organ dysfunction, septic shock and ultimately death. Healthcare professionals have become much more aware of endotoxemia over the last several years, and many of the emerging therapies for sepsis now advancing though clinical trials target endotoxin," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "The growing awareness of endotoxemia, and the increasing number of therapies being developed for this indication, position us well to drive adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment."

Highlights from 2007:

- Entered into an exclusive agreement in November 2007 with Toray

Medical Co. Ltd. to distribute Spectral's EAA(TM) Endotoxin Activity

Assay in Japan. Toray Medical will market and sell the EAA(TM) in

conjunction with its Toraymyxin blood purification device, which

removes endotoxin from the bloodstream. Toray Medical will also

distribute the EAA(TM) diagnostic as a stand-alone product.

- Launched the EAA(TM) in Germany in September 2007 through A. Menarini

Diagnostics Deutschland, building on a distribution agreement signed

in May 2007 which covers Germany and includes an option to extend the

arrangement to the rest of Europe.

- Expanded its EAA(TM) product distribution agreement in Italy with its

partner Estor, SpA in May 2007. The expanded agreement is aimed at

increasing the number of hospitals in Italy utilizing the EAA(TM)

assay, particularly in combination with the Toraymyxin blood

purification device.

- Entered into a non-exclusive license and material supply agreement in

November 2007 with Bio-Rad Pasteur S.A., a leader in the manufacturing

and distribution of products for the life science research and

clinical diagnostics markets. Spectral will provide Bio-Rad with its

proprietary single chain Troponin I reagents, which are now being sold

by five major international reagent supply and instrumentation

companies.

- Upgraded manufacturing facilities to be self sufficient for the

manufacture of its EAA(TM) product and its proprietary reagent

products.

Financial Review

The financial statements apply to the year ended December 31, 2007 and the nine months ended December 31, 2006.

For the year ended December 31, 2007, the Company reported sales of $2,993,000 compared to $2,169,000 for the nine month period in 2006. Sales in 2007 were primarily comprised of the Company's EAA(TM) product and its Troponin I reagents. On an annualized basis there was a marginal increase in sales levels, however, three significant EAA(TM) distribution agreements were signed in the last half of 2007 that management anticipates will positively affect revenues going forward.

Operating expenses of $3,915,000 were closely managed in 2007 and remained consistent with spending levels for the nine months ended December 31, 2006, reflecting the Company's low cost operating structure.

The Company reported a Fiscal 2007 loss of $1,666,000 ($0.07 per share) compared to net income of $3,730,000 ($0.16 per share) for the nine months ended December 31, 2006. Net Income for the nine month period last year included a one time gain of $5,363,000 ($0.23 cents per share) on the settlement of certain convertible notes payable.

At December 31, 2007, the Company had cash and short-term investments totaling $4,927,000, compared to $6,002,000 as at December 31, 2006.

The total number of shares outstanding for the Company was 24,118,424 as at March 6, 2008.

Notice of Annual General Meeting

Spectral will hold its Annual General Meeting of Shareholders at 4:00 PM on May 13, 2008 at the offices of Stikeman, Elliott LLP, Suite 5300, 199 Bay Street, Toronto, Ontario.

About Spectral Diagnostics

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX has not reviewed and does not accept responsibility for the

adequacy or accuracy of this statement.

Summary financial statements attached:

Spectral Diagnostics Inc.

Balance Sheets

-------------------------------------------------------------------------

As at December 31, 2007 and 2006

(in thousands of dollars)

2007 2006

$ $

Assets

Current assets

Cash and cash equivalents 638 945

Short-term investments 4,289 5,057

Accounts receivable 677 762

Inventories 249 155

Prepaid expenses 55 130

-------------------------

5,908 7,049

Property, plant and equipment, net 379 235

Commercial instruments, net 164 29

Purchased technology and trademarks, net 1,529 2,022

-------------------------

7,980 9,335

-------------------------

-------------------------

Liabilities

Current liabilities

Accounts payable and accrued liabilities 379 504

Deferred revenue 150 -

Convertible note payable 2,008 1,843

-------------------------

2,537 2,347

-------------------------

Shareholders' Equity

Common shares 2,524 2,520

Other equity 5,606 5,489

Deficit (2,687) (1,021)

-------------------------

5,443 6,988

-------------------------

7,980 9,335

-------------------------

-------------------------

Spectral Diagnostics Inc.

Statements of Operations, Comprehensive (Loss) Income and Deficit

-------------------------------------------------------------------------

(in thousands of dollars, except share and per share data)

Year Nine months

ended ended

December December

31, 2007 31, 2006

$ $

Sales 2,993 2,169

Cost of sales 803 583

-------------------------

Gross margin 2,190 1,586

-------------------------

Operating expenses

Selling, general and administrative 3,167 2,395

Amortization 588 580

Foreign exchange loss 102 34

Stock-based compensation 117 358

Research and product development,

net of tax credits (59) (239)

-------------------------

3,915 3,128

-------------------------

Loss before the following (1,725) (1,542)

Interest expense on convertible notes payable (165) (288)

Other net interest income 224 197

Gain on settlement of convertible

notes payable - 5,363

-------------------------

Net (loss) income and comprehensive (loss)

income for the period (1,666) 3,730

Deficit - Beginning of period (1,021) (103,671)

Restatement of capital - 98,920

-------------------------

Deficit - End of period (2,687) (1,021)

-------------------------

-------------------------

Basic (loss) earnings per common share (0.07) 0.16

-------------------------

-------------------------

Diluted (loss) earnings per common share (0.07) 0.14

-------------------------

-------------------------

Weighted average number of common

shares outstanding 24,117,333 22,874,694

-------------------------

-------------------------

Spectral Diagnostics Inc.

Statements of Cash Flows

-------------------------------------------------------------------------

(in thousands of dollars)

Year Nine months

ended ended

December December

31, 2007 31, 2006

$ $

Cash provided by (used in)

Operating activities

Net (loss) income and comprehensive (loss)

income for the period (1,666) 3,730

Items not affecting cash

Amortization 588 580

Amortization of commercial instruments

included in cost of sales 11 12

Loss on disposal of property, plant

and equipment 46 -

Write off of purchased technology

and trademarks 66 -

Stock-based compensation expense 117 358

Interest on convertible notes payable 165 288

Gain on settlement of convertible

notes payable - (5,363)

Changes in non-cash working capital (59) (664)

-------------------------

(732) (1,059)

-------------------------

Investing activities

Purchase of property, plant and equipment (280) (157)

Purchase of technology and trademarks (44) (22)

Purchase of commercial instruments (173) (113)

Decrease (increase) in short-term investments 768 (1,707)

Deferred revenue 150 -

-------------------------

421 (1,999)

-------------------------

Financing activities

Issuance of common shares 4 -

-------------------------

Decrease in cash and cash equivalents

during the period (307) (3,058)

Cash and cash equivalents

- Beginning of period 945 4,003

-------------------------

Cash and cash equivalents - End of period 638 945

-------------------------

-------------------------

Non-cash investing and financing activities

Settlement of existing convertible

notes payable - (9,801)

Issuance of new convertible note payable - 1,761

Issuance of common shares on settlement

of convertible notes payable - 1,994

Issuance of warrants on settlement

of convertible notes payable - 168


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is ... projects are designed, built and brought to market. , The Design Lab is ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
Breaking Biology News(10 mins):